Analysts await EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) to report earnings on Mar, 15 for the fiscal quarter ending Dec 2015.

They expect $-0.52 EPS, up 53.85% or $0.28 from last year’s $-0.8 per share.

At the moment 4 analysts are watching EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), 3 rate it “Buy”, 1 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 1 analyst has a mean sales target of 2.10 million. For the quarter ending Jun-16, 1 analyst has a mean sales target of 2.80 million whilst for the year ending Dec-16, 3 analysts have a mean target of 5.57 million.

In terms of earnings per share, 1 analyst has a -0.52 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 1 analyst has a -0.44 EPS mean target and for the quarter ending Jun-16 there are 3 estimates of -1.88 EPS.

The biggest institutional shareholders in EPIRUS Biopharmaceuticals, Inc. include 5AM Partners III, LLC which owns 3 million shares in the company valued at $12.94 million. Jennison Associates LLC is the second biggest holder with 3 million shares currently valued at 8.03 million whilst Camber Capital Management LLC has 2 million shares valued at 5.71 million.

Total shares held by institutions as of the most recent company filings are 16,867,660 with a reported 1,320,566 bought and 20,446,752 sold. These holdings make up 70.76% of the company’s outstanding shares.

Currently insiders hold 4,090,993 shares in the business which makes up 16.78% of shares. The biggest holder currently is Christopher C. Gallen who owns 1,842,986 shares (7.56% of those outstanding), whilst Snutch Terrance P. holds 602,603 (2.47% of shares outstanding) and Alexis Borisy,A.M. holds 312,204 (1.28% of shares outstanding).

The stock increased 4.32% or $0.13 during the last trading session, hitting $7.87. EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) has risen 24.9% over the past 6 months and is uptrending.